公开(公告)号：US20130030006A1

公开(公告)日：2013-01-31

申请号：US13640824

申请日：2011-04-27

申请人： Akiyoshi Someya ,  Hiroko Hayashida ,  Mai Koda ,  Masayuki Tanahashi ,  Katsuro Yoshioka

发明人： Akiyoshi Someya ,  Hiroko Hayashida ,  Mai Koda ,  Masayuki Tanahashi ,  Katsuro Yoshioka

IPC分类号： A61K31/496 ,  A61P29/00 ,  C07D413/14 ,  A61P13/08 ,  A61K31/4545 ,  C07D401/14 ,  C07D401/12 ,  A61P13/10

CPC分类号： C07D401/12 ,  A61K31/4545 ,  A61K31/496 ,  C07D213/65 ,  C07D213/80 ,  C07D401/14 ,  C07D413/14

摘要： [Problem] Provided is an agent for preventing or treating diseases accompanied by urinary pain.[Means for Solution] A pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or a salt thereof was confirmed to have not only an action of increasing effective bladder capacity but also an analgesic action against bladder pain and testis pain, based on FAAH inhibitory action. Accordingly, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or a salt thereof can be used for preventing or treating interstitial cystitis/bladder pain syndrome and/or chronic nonbacterial prostatitis/chronic pelvic pain syndrome.

摘要翻译： [问题]提供用于预防或治疗伴有尿痛的疾病的药剂。 [解决方案]确认吡啶基非芳香族含氮杂环-1-羧酸酯化合物或其盐不仅具有增加膀胱有效能力的作用，而且还具有针对膀胱疼痛和睾丸疼痛的镇痛作用，基于 FAAH抑制作用。 因此，吡啶基非芳香族含氮杂环-1-羧酸酯化合物或其盐可用于预防或治疗间质性膀胱炎/膀胱疼痛综合征和/或慢性非细菌性前列腺炎/慢性盆腔疼痛综合征。

公开(公告)号：US20110212973A1

公开(公告)日：2011-09-01

申请号：US13126980

申请日：2009-11-05

申请人： Takahiro Ishii ,  Takashi Sugane ,  Ryosuke Munakata ,  Satoshi Aoki ,  Masahide Higaki ,  Akiyoshi Someya

发明人： Takahiro Ishii ,  Takashi Sugane ,  Ryosuke Munakata ,  Satoshi Aoki ,  Masahide Higaki ,  Akiyoshi Someya

IPC分类号： A61K31/496 ,  C07D405/14 ,  C07D417/14 ,  C07D409/14 ,  C07D413/14 ,  C07D401/14 ,  A61P13/00 ,  A61P13/10 ,  A61P13/08

CPC分类号： A61K31/496 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/04 ,  C07D417/12

摘要： [Problems] A compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases is provided.[Means for Solution] The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that a piperazine-1-carboxylate compound, in which benzimidazol-2-ylcarbonyl, benzofuran-2-ylcarbonyl or the like binds to the 4-position of the piperazine, has an excellent FAAH inhibitory activity and further has an action to increase the effective bladder capacity, an action to ameliorate sleep disorders, an anti-diuretic action, and an analgesic activity on lower urinary tract pain including bladder pain and the like, thereby completed the present invention. The carbamate compound of the present invention has an excellent FAAH inhibitory activity and can be used as an agent for preventing and/or treating FAAH-related diseases, particularly nocturia, interstitial cystitis, painful bladder syndrome, or chronic non-bacterial prostatitis/chronic pelvic pain syndrome.

摘要翻译： [问题]提供了用作治疗FAAH相关疾病的药物组合物的活性成分的化合物。 [解决方案]本发明人对具有FAAH抑制活性的化合物进行了广泛的研究，结果发现了哌嗪-1-羧酸酯化合物，其中苯并咪唑-2-基羰基，苯并呋喃-2-基羰基或 类似物与哌嗪的4-位结合，具有优异的FAAH抑制活性，并且还具有增加膀胱有效能力的作用，改善睡眠障碍的作用，抗利尿作用和对下尿路的止痛活性 包括膀胱疼痛等的道痛，从而完成了本发明。 本发明的氨基甲酸酯化合物具有优异的FAAH抑制活性，可用作预防和/或治疗FAAH相关疾病，特别是夜尿症，间质性膀胱炎，疼痛膀胱综合征或慢性非细菌性前列腺炎/慢性骨盆 疼痛综合征。